Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System

References

• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
   PubMed Web of Science ®Google Scholar
• Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States,2010. JAMA. 2013;309:657–659.
   PubMed Web of Science ®Google Scholar
• Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569–576.
   PubMed Web of Science ®Google Scholar
• Ballantyne JC. Assessing the prevalence of opioid misuse, abuse, and addiction in chronic pain. Pain. 2015;156:567–568.
   PubMed Web of Science ®Google Scholar
• Frieden TR, Houry D. Reducing the risks of relief–the CDC opioid-prescribing guideline. N Engl J Med. 2016;374:1501–1504.
   PubMed Web of Science ®Google Scholar
• Guidance for industry. Abuse-deterrent opioids – evaluation and labeling. final guidance [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Oct 30]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
   Google Scholar
• Dum J, Blasig J, Herz A. Buprenorphine: demonstration of physical dependence liability. Eur J Pharmacol. 1981;70:293–300.
   PubMed Web of Science ®Google Scholar
• Lee KO, Akil H, Woods JH, et al. Differential binding properties of oripavines at cloned m- and d-opioid receptors. Eur J Pharmacol. 1999;378:323–330.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61:101–110.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manag. 2005;29:297–326.
   PubMed Web of Science ®Google Scholar
• Butrans® [full prescribing information]. Stamford (CT): Purdue Pharma L.P.; 2014 [cited 2016 Nov 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021306s015s019lbl.pdf
   Google Scholar
• Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977;60:547–554.
   PubMed Web of Science ®Google Scholar
• Lizasoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol. 1991;22:297–300.
   PubMedGoogle Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569–580.
   PubMed Web of Science ®Google Scholar
• Umbricht A, Huestis MA, Cone EJ, et al. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol. 2004;24:479–487.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428–450.
   PubMed Web of Science ®Google Scholar
• Christoph T, Kogel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol. 2005;507:87–98.
   PubMed Web of Science ®Google Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13:219–230.
   PubMed Web of Science ®Google Scholar
• Schedule of controlled substances: proposed rule: rescheduling of buprenorphine from schedule V to schedule III [Internet]. Springfield (VA): DEA Office of Division Control; [cited 2016 Oct 30]. Available from: http://www.deadiversion.usdoj.gov/fed_regs/rules/2002/fr0321.htm
   Google Scholar
• Federal Food, Drug and Cosmetic Act - Title 21: food and drugs, chapter 13: drug abuse prevention and control, subchapter 1: control and enforcement [Internet]. Springfield (VA): DEA Office of Division Control; [cited 2016 Oct 30]. Available from: http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm#cntlsbb
   Google Scholar
• Striebel JM, Kalapatapu RK. The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med. 2014;47:169–174.
   PubMed Web of Science ®Google Scholar
• Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatr. 2016;173:491–498.
   PubMed Web of Science ®Google Scholar
• Kapil R, Cipriano A, Friedman K, et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manag. 2013;46:65–75.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–1268.
   PubMed Web of Science ®Google Scholar
• Steiner D, Munera C, Hale M, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12:1163–1173.
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manag. 2011;42:903–917.
   PubMed Web of Science ®Google Scholar
• Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32:844–860.
   PubMed Web of Science ®Google Scholar
• Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15:169–178.
   PubMed Web of Science ®Google Scholar
• James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manag. 2010;40:266–278.
   PubMed Web of Science ®Google Scholar
• Munera C, Drehobl M, Sessler NE, et al. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag. 2010;6:193–202.
   PubMedGoogle Scholar
• Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther. 2007;29:2179–2193.
   PubMed Web of Science ®Google Scholar
• Yarlas A, Miller K, Wen W, et al. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. J Pain. 2013;14:14–23.
   PubMed Web of Science ®Google Scholar
• Miller K, Yarlas A, Wen W, et al. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother. 2013;14:269–277.
   PubMed Web of Science ®Google Scholar
• Miller K, Wen W, Lynch SY, et al. Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low back pain: results from two randomized controlled trials. Pain Pract. 2016;16:345–358.
   PubMed Web of Science ®Google Scholar
• Yarlas A, Miller K, Wen W, et al. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. Postgrad Med. 2015;127:38–45.
   PubMed Web of Science ®Google Scholar
• Dasgupta N, Davis J, Jonsson Funk M, et al. Using poison center exposure calls to predict methadone poisoning deaths. PLoS One. 2012;7:e41181.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–1282.
   PubMed Web of Science ®Google Scholar
• Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clinical Toxicol. 2007;45:144–151.
   PubMed Web of Science ®Google Scholar
• Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–442.
   PubMed Web of Science ®Google Scholar
• Smith MY, Schneider MF, Wentz A, et al. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: a comparison of two approaches. Clinical Toxicol. 2007;45:23–30.
   PubMed Web of Science ®Google Scholar
• Smith MY, Irish W, Wang J, et al. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers. Pharmacoepidemiol Drug Saf. 2008;17:1050–1059.
   PubMed Web of Science ®Google Scholar
• Bailey JE, Barton PL, Lezotte D, et al. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend. 2006;84:182–187.
   PubMed Web of Science ®Google Scholar
• National Poison Data System (NPDS) [Internet]. Alexandria (VA): American Association of Poison Control Centers; [cited 2016 Oct 30]. Available from: http://www.aapcc.org/data-system/
   Google Scholar
• CDC Fact Sheet: Using the National Poisoning Data System for Public Health Surveillance. A collaborative effort of the Centers for Disease Control and Prevention and the American Association of Poison Control Centers [Internet]. Atlanta (GA): Department of Health and Human Services Centers for Disease Control and Prevention; 2005 [cited 2016 Oct 30]. Available from: http://www.cdc.gov/nceh/hsb/chemicals/pdfs/npds.pdf
   Google Scholar
• Mowry JB, Spyker DA, Cantilena LR, et al. 2013 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st annual report. Clin Toxicol. 2014;52:1032–1283.
   PubMed Web of Science ®Google Scholar
• HSRN data brief: National Prescription Audit [Internet]. Collegeville (PA): IMS Health Informatics; 2011 [cited 2016 Oct 30]. Available from: https://www.imshealth.com/files/web/IMSH%20Institute/NPA_Data_Brief-.pdf
   Google Scholar
• Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open. 2015;5:e007629.
   PubMed Web of Science ®Google Scholar
• Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York city. Drug Alcohol Depend. 2015;155:298–301.
   PubMed Web of Science ®Google Scholar
• Wiegand TJ, Le Lait MC, Bartelson BB, et al. Analysis of the abuse and diversion of the buprenorphine transdermal delivery system. J Pain. 2016;17:745–752.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105:709–718.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49–57.
   PubMed Web of Science ®Google Scholar
• Emrich HM, Vogt P, Herz A, et al. Antidepressant effects of buprenorphine. Lancet. 1982;320:709.
   Google Scholar
• Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28:593–595.
   PubMed Web of Science ®Google Scholar
• Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacol. 2015;40:1448–1455.
   PubMed Web of Science ®Google Scholar
• Davis JM, Severtson SG, Bucher-Bartelson B, et al. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits. Pharmacoepidemiol Drug Saf. 2014;23:18–25.
   PubMed Web of Science ®Google Scholar
• National drug code database background information [Internet]. Silver Spring (MD): US Food and Drug Administration; 2012 [cited 2016 Oct 30]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/UCM070829
   Google Scholar
• Dolophine (methadone hydrochloride) [full prescribing information]. Columbus (OH): Roxane Laboratories, Inc; [cited 2016 Nov 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/006134s038lbl.pdf
   Google Scholar
• US Food and Drug Administration (FDA). What are extended-release and long-acting (ER/LA) opioid analgesics products? [cited 2016 Nov 30]. Available from: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=17
   Google Scholar
• Pergolizzi JV Jr, Ben-Joseph R, Chang CL, et al. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Curr Med Res Opin. 2014;30:1579–1587.
   PubMed Web of Science ®Google Scholar
• SAMHSA, Center for Behavioral Health Statistics and Quality. 2014 National survey on drug use and health: detailed tables. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015 [cited 2016 Nov 30]. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf
   Google Scholar